CompletedPhase 2

A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers

United States172 participantsStarted 2002-11

Plain-language summary

Bacterial corneal ulcers are a leading cause of pediatric blindness in underdeveloped countries due to a lack of antibiotic availability and affordability, among other reasons. Povidone-iodine, an inexpensive and readily available broad-spectrum antimicrobial agent, may be an effective and affordable treatment for corneal ulcers, allowing preservation of sight for those afflicted with this disease.

Who can participate

Age range1 Month

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Clinical diagnosis of untreated bacterial corneal ulcer that began within 14 days of presentation to the study center. * Corneal ulcer size is 2 mm-8 mm. in diameter, and does not extend to the limbus. Exclusion Criteria: * Topical or systemic antimicrobial or immunosuppressant therapy within 14 days of presentation to the study center. * Corneal ulcer smear and culture fail to show the presence of bacteria. * Allergic history to povidone-iodine, iodine or any components of Neosporin. * Dacrocystitis, neurotropic or exposure keratitis, keratitis sicca, positive HIV status, and legal blindness in the unaffected eye.

What they're measuring

Days to cure, with corneal epithelial defect closed, and no inflammatory signs other than minimal injection.

Safety of study medication use compared to control medications. No untoward reactions or loss of visual acuity (VA) compared with pre-treatment VA findings.

Trial details

NCT IDNCT00386958

SponsorLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2006-01

View on ClinicalTrials.gov More Infected Corneal Ulcers trials